CSNK1A1 and myelodysplastic syndrome: The activation of the p53 pathway by inhibition of CK1α has shown promising preclinical activities in MDS, AML, and MM, leading to the establishment of clinical trials for the first CK1α inhibitor (BTX-A51, NCT04243785).